CO2023006437A2 - Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de enfermedades renales provocadas por o acompañadas de la enfermedad de fabry - Google Patents
Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de enfermedades renales provocadas por o acompañadas de la enfermedad de fabryInfo
- Publication number
- CO2023006437A2 CO2023006437A2 CONC2023/0006437A CO2023006437A CO2023006437A2 CO 2023006437 A2 CO2023006437 A2 CO 2023006437A2 CO 2023006437 A CO2023006437 A CO 2023006437A CO 2023006437 A2 CO2023006437 A2 CO 2023006437A2
- Authority
- CO
- Colombia
- Prior art keywords
- accompanied
- prevention
- fusion protein
- diseases caused
- treatment
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152247 | 2020-11-13 | ||
| PCT/KR2021/016630 WO2022103221A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006437A2 true CO2023006437A2 (es) | 2023-06-09 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006437A CO2023006437A2 (es) | 2020-11-13 | 2023-05-16 | Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de enfermedades renales provocadas por o acompañadas de la enfermedad de fabry |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (https=) |
| EP (1) | EP4245311A4 (https=) |
| JP (1) | JP2023549323A (https=) |
| KR (1) | KR20220065719A (https=) |
| CN (1) | CN116419760A (https=) |
| AU (1) | AU2021378707A1 (https=) |
| CA (1) | CA3196258A1 (https=) |
| CO (1) | CO2023006437A2 (https=) |
| IL (1) | IL302858A (https=) |
| MX (1) | MX2023005580A (https=) |
| WO (1) | WO2022103221A1 (https=) |
| ZA (1) | ZA202304534B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR133746A1 (es) * | 2023-09-14 | 2025-10-29 | Green Cross Corp | NUEVA FORMULACIÓN LIOFILIZADA QUE CONTIENE PROTEÍNA DE FUSIÓN a-GALACTOSIDASA A |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| PT3345615T (pt) * | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| AU2018295994B2 (en) * | 2017-07-07 | 2025-02-06 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
| FR3069340A1 (fr) * | 2017-07-21 | 2019-01-25 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| CN111511910B (zh) * | 2017-12-22 | 2024-11-08 | 韩美药品株式会社 | 具有新颖结构的治疗酶融合蛋白及其用途 |
-
2021
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023549323A (ja) | 2023-11-24 |
| US20230405093A1 (en) | 2023-12-21 |
| AU2021378707A1 (en) | 2023-06-01 |
| CA3196258A1 (en) | 2022-05-19 |
| KR20220065719A (ko) | 2022-05-20 |
| EP4245311A4 (en) | 2024-10-30 |
| IL302858A (en) | 2023-07-01 |
| WO2022103221A1 (ko) | 2022-05-19 |
| CN116419760A (zh) | 2023-07-11 |
| MX2023005580A (es) | 2023-05-29 |
| ZA202304534B (en) | 2024-10-30 |
| EP4245311A1 (en) | 2023-09-20 |
| AU2021378707A9 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000873A1 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. | |
| CO2021000326A2 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas | |
| BR112021013415A2 (pt) | Proteínas de fusão multifuncionais e usos das mesmas | |
| MX2020007072A (es) | Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma. | |
| CY1107248T1 (el) | Συντηγμενες πρωτεϊνες | |
| EA200901211A1 (ru) | Антигены белка с5 и их применение | |
| AR102522A1 (es) | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a | |
| AR106753A1 (es) | Proteínas de unión a ctla4p | |
| GT200900248A (es) | "proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpo, que unen especificamente a cd154 y sus usos" | |
| MA49727B1 (fr) | Anticorps et polypeptides dirigés contre cd127 | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| CR8108A (es) | Tratamiento con anticuerpos anti-vegf | |
| NZ598834A (en) | Prevention, treatment and diagnosis of P. gingivalis infection | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
| CO2023006437A2 (es) | Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de enfermedades renales provocadas por o acompañadas de la enfermedad de fabry | |
| MX2024012898A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| CL2023003331A1 (es) | Anticuerpos anti-tmprs66 y usos de los mismos. | |
| WO2022184854A3 (en) | Formulations of ace2 fc fusion proteins | |
| CO2023006516A2 (es) | Uso de una proteína de fusión enzimática terapéutica en la prevención y el tratamiento de la neuropatía provocada por o acompañada de la enfermedad de fabry | |
| BRPI0514124A (pt) | anticorpos monoclonais humanos contra a il-4 humana | |
| DOP2024000117A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| MX2024009171A (es) | Formas truncadas de la iga proteasa, proteinas de fusion que comprenden una forma truncada de la iga proteasa y usos de estas. |